Botto M, Fong K Y, So A K, Koch C, Walport M J
Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.
J Exp Med. 1990 Oct 1;172(4):1011-7. doi: 10.1084/jem.172.4.1011.
C3 exhibits two common allotypic variants that may be separated by gel electrophoresis and are called C3 fast (C3 F) and C3 slow (C3 S). C3 F, the less common variant, occurs at appreciable frequencies only in Caucasoid populations (gene frequency = 0.20). An increased prevalence of the C3 F allele has been reported in patients with partial lipodystrophy, IgA nephropathy, and Indian childhood hepatic cirrhosis. Studies of the genomic organization of the human C3 gene led to the identification of a single change (C to G) between C3 S and C3 F at nucleotide 364 in exon 3. This leads, at the translation level, to the substitution of an arginine residue (positively charged) in C3 S for a glycine residue (neutral) in C3 F. This substitution results in a polymorphic restriction site for the enzyme HhaI. The resulting restriction fragment length polymorphism (RFLP) was investigated using genomic DNA, amplified using the polymerase chain reaction; there was absolute concordance between the genomic polymorphism and the distribution of C3 S and C3 F in 50 normal subjects. The molecular basis of a second structural polymorphism, defined by the monoclonal antibody HAV 4-1, was also characterized. The polymorphic determinant was identified at codon 314 in the exon 9 of the beta chain where a leucine residue (HAV 4-1+) is substituted for a proline residue (HAV 4-1-). Identification of the amino acid sequences of these polymorphic variants will facilitate characterization of possible functional differences between different allotypes of C3. Three RFLPs (BamHI, EcoRI, and SstI) were located to introns in the C3 gene. There was no allelic association between these three RFLPs, or between the RFLPs and the C3 F/S polymorphic site. Genetic equilibration of these polymorphisms has occurred within a gene of 41 kb.
C3有两种常见的同种异型变体,可通过凝胶电泳分离,分别称为C3快型(C3 F)和C3慢型(C3 S)。C3 F是较不常见的变体,仅在白种人群体中以可观的频率出现(基因频率 = 0.20)。据报道,在部分脂肪营养不良、IgA肾病和印度儿童肝硬化患者中,C3 F等位基因的患病率增加。对人类C3基因的基因组组织研究导致在第3外显子的核苷酸364处鉴定出C3 S和C3 F之间的单个变化(C到G)。这在翻译水平上导致C3 S中的精氨酸残基(带正电荷)被C3 F中的甘氨酸残基(中性)取代。这种取代产生了酶HhaI的多态性限制性位点。使用聚合酶链反应扩增的基因组DNA研究了由此产生的限制性片段长度多态性(RFLP);在50名正常受试者中,基因组多态性与C3 S和C3 F的分布之间存在完全一致性。还对由单克隆抗体HAV 4-1定义的第二种结构多态性的分子基础进行了表征。多态性决定簇在β链第9外显子的314密码子处被鉴定,其中亮氨酸残基(HAV 4-1+)被脯氨酸残基(HAV 4-1-)取代。鉴定这些多态性变体的氨基酸序列将有助于表征C3不同同种异型之间可能的功能差异。三个RFLP(BamHI、EcoRI和SstI)位于C3基因的内含子中。这三个RFLP之间,或RFLP与C3 F/S多态性位点之间没有等位基因关联。这些多态性在41 kb的基因内已达到遗传平衡。